Tag Archives: Derek Archila

Stifel Nicolaus Believes NGM Biopharmaceuticals (NASDAQ: NGM) Won’t Stop Here

Stifel Nicolaus analyst Derek Archila reiterated a Buy rating on NGM Biopharmaceuticals (NGM – Research Report) on May 13 and set a price target of $32.00. The company’s shares closed last Friday at $22.08, close to its 52-week high of

Principia Biopharma (PRNB) Received its Third Buy in a Row

After H.C. Wainwright and Wells Fargo gave Principia Biopharma (NASDAQ: PRNB) a Buy rating last month, the company received another Buy, this time from Stifel Nicolaus. Analyst Derek Archila reiterated a Buy rating on Principia Biopharma yesterday and set a

AnaptysBio (ANAB) Gets a Hold Rating from Stifel Nicolaus

In a report released today, Derek Archila from Stifel Nicolaus reiterated a Hold rating on AnaptysBio (ANAB – Research Report), with a price target of $17.00. The company’s shares closed last Wednesday at $17.50, close to its 52-week low of

Rhythm Pharmaceuticals (RYTM) Received its Third Buy in a Row

After Needham and Morgan Stanley gave Rhythm Pharmaceuticals (NASDAQ: RYTM) a Buy rating last month, the company received another Buy, this time from Stifel Nicolaus. Analyst Derek Archila reiterated a Buy rating on Rhythm Pharmaceuticals today and set a price

Viking Therapeutics (VKTX) Gets a Buy Rating from Stifel Nicolaus

In a report released yesterday, Derek Archila from Stifel Nicolaus reiterated a Buy rating on Viking Therapeutics (VKTX – Research Report), with a price target of $14.00. The company’s shares closed last Thursday at $5.76. According to TipRanks.com, Archila is

Stifel Nicolaus Remains a Hold on Amarin (AMRN)

In a report released today, Derek Archila from Stifel Nicolaus reiterated a Hold rating on Amarin (AMRN – Research Report), with a price target of $8.00. The company’s shares closed last Thursday at $7.55, close to its 52-week low of